Ras Therapeutics Ras Therapeutics
Ras Therapeutics Contact Ras Therapeutics
Ras Therapeutics
Contact Ras Therapeutics Ras Therapeutics Homepage
Therapeutics
Ras Therapeutics HomepageRas TherapeuticsTechnology - Ras TherapeuticsRas TherapeuticsScientific Advisory Board - Ras TherapeuticsRas TherapeuticsManagement - Ras TherapeuticsRas TherapeuticsContact Ras Therapeutics
Therapeutics, Onconlogy
Ras Therapeutics, Oncology, Cancer Treatment
Therapeutics, Cancer Treatment

Pancreatic cancer ranks as the 4th leading cause of cancer death in the U.S., costing over $2.6 billion in total health care costs, yet it is one of the few cancers for which survival has not improved substantially over the past 30 years. In 2009, it was estimated that over 42,400 individuals would be diagnosed with and nearly 35,200 will die of pancreatic cancer in the United States. The average life expectancy of a newly diagnosed pancreatic cancer patient is approximately 3-6 months; the five-year survival rate is only about 5%.

Ras Therapeutics aspires to bring new hope to sufferers of pancreatic and other cancers with new treatment options and the advancement of clinical trials methodologies.
oncology
Copyright © 2007 Ras Therapeutics, Inc. All rights reserved.